Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

AlphaGen and ArtBio Form China-US Partnership for Radioligand Therapies

publication date: Feb 21, 2024

Shanghai AlphaGen Therapeutics and ArtBio of Cambridge MA, two targeted radioligand therapy (RLT) companies, forged a far-reaching agreement to expand AriBio’s market and develop new RLTs. AlphaGen will have China rights to use ArtBio’s AlphaDirect™ isotope isolation technology to generate 212Pb, a unique isotope without a global supply. It will also have a license to develop AB001, a clinical-stage alpha RLT targeting prostate-specific membrane antigen (PSMA), in Greater China. And AlphaGen will have the right to use ArtBio’s AlphaDirect™ platform to develop 212Pb RLTs against additional targets. ArtBio will have a minority equity interest in AlphaGen as part of the agreement. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital